NCT03532542: A reported trial by Sarepta Therapeutics, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03532542 |
|---|---|
| Title | Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 2, 2018 |
| Completion date | July 26, 2023 |
| Required reporting date | July 25, 2024, midnight |
| Actual reporting date | July 24, 2024 |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |